A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 May 2018

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Cellulite
  • Focus Registrational; Therapeutic Use
  • Acronyms RELEASE; RELEASE-2
  • Sponsors Endo Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2018 According to a BioSpecifics Technologies Corporation media release, top-line results are expected in the first quarter of 2019.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top